The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek clearance for new products.
Dexcom receives warning letter based on FDA inspections of 2 plants | MedTech Dive
Reactions
Leave a Reply to childishrational
I wish they weren’t obviously designed to fail way sooner than they should.